Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 4 recruiting now full pipeline small index

Hypoparathyroidism: full-pipeline trial registry

4 of 11 indexed Hypoparathyroidism trials are currently recruiting.

Corpus placement: #1,577 of 28,707 conditions by registered trial count.

11 US clinical trials · 4 currently recruiting · #1,577 of 28,707 conditions by registered trial count

Hypoparathyroidism: 11 US clinical trials tracked, 4 recruiting.

Hypoparathyroidism is the subject of 11 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 4 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Shire, running 3 of these trials.

Enrollment posture brief

Registry condition hypoparathyroidism

OPEN 4 | RECR 36% | LATE 4 | EARLY 3 | RANK #1577 | SPON 3

Nearest open-share peer: Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive (36% recruiting · 11 trials)

Acute Pancreatitis81.8%Acute Stroke45.5%Acquired Brain Injury36.4%Hypoparathyroidism (this)36%Acute Lung Injury9.1%
Open-enrollment share among volume-matched conditions near Hypoparathyroidism

Hypoparathyroidism lists 4 open slots (36% of 11 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Hypoparathyroidism on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Hypoparathyroidism is recruiting below its size-band peers.

    4 of 11 indexed trials (36.4%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Hypoparathyroidism research.

    Shire accounts for 3 of 11 trials (27.3%). 8 distinct sponsors appear on at least one study for this condition label.

  3. Most Hypoparathyroidism trials plan to enrol fewer than 100 people.

    Median target enrolment is 64 among the 11 trials that report a genuine target (sentinel values excluded). 7 of those (63.6%) plan for fewer than 100 participants.

  4. Hypoparathyroidism splits between interventional and observational designs.

    7 interventional and 4 observational studies make up this index (63.6% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 11Phase 22Phase 31Phase 43

Open and recent trials

11 total, page 1 of 1

RECRUITING 106 participants

Hypoparathyroidism Natural History Study

Columbia University

NCT05793853

RECRUITING 100 participants

Routine Validation and Reproducibility Testing of Laboratory Assays and Research Techniques Used for Endocrine, Cardiometabolic, and Musculoskeletal Disorder Research (VALD)

Bettina Mittendorfer

NCT07083557

RECRUITING 50 participants

A Global Pregnancy Registry to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to YORVIPATH® (Palopegteriparatide) During Pregnancy and Breastfeeding

Ascendis Pharma A/S

NCT07345494

RECRUITING Phase 1 3 participants

Parathyroid Allotransplant for Treatment of Hypoparathyroidism

Peter Stock

NCT06961071

ACTIVE NOT RECRUITING 1,339 participants

A Registry for Participants With Chronic Hypoparathyroidism

Takeda

NCT01922440

ACTIVE NOT RECRUITING Phase 2 60 participants

Extension Study to Evaluate the Long-Term Safety and Tolerability of MBX 2109 in Patients With Hypoparathyroidism

MBX Biosciences

NCT06531941

COMPLETED Phase 3 124 participants

Use of NPSP558 in the Treatment of Hypoparathyroidism

Shire

NCT00732615

COMPLETED Phase 4 93 participants

A Study to Learn if Recombinant Human Parathyroid Hormone [rhPTH(1-84)] Can Improve Symptoms and Metabolic Control in Adults With Hypoparathyroidism (BALANCE)

Shire

NCT03324880

COMPLETED Phase 2 64 participants

Safety, Pharmacokinetics and Efficacy of MBX 2109 in Patients With Hypoparathyroidism

MBX Biosciences

NCT06465108

COMPLETED Phase 4 39 participants

A Study of Extended Use of Recombinant Human Parathyroid Hormone (rhPTH(1-84)) in Hypoparathyroidism

Shire

NCT02910466

COMPLETED Phase 4 19 participants

Does Treatment of Hypovitaminosis D Increase Calcium Absorption?

University of Wisconsin, Madison

NCT00581828

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 2
Phase 3 1
Phase 4 3

Top Sponsors

Named interventions

Most-linked intervention names on Hypoparathyroidism records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

rhPTH (1-84) Biological
1 trials
MBX 2109 Drug
1 trials
rhPTH(1-84) Drug
1 trials
NPSP558 Drug
1 trials
Vitamin D Drug
1 trials
200-1600 µg of MBX 2109 once-weekly by subcutaneous injection Drug
1 trials
400 µg of MBX 2109 once-weekly by subcutaneous injection Drug
1 trials
Parathyroid Allotransplant Biological
1 trials

US sites by state

Facility locations filed on Hypoparathyroidism trials. A trial with sites in several states counts in each.

New York 5 trials
Ohio 4 trials
Illinois 4 trials
Florida 4 trials
California 4 trials
Pennsylvania 3 trials
North Carolina 3 trials
Missouri 3 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Hypoparathyroidism page

11 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 4 Hypoparathyroidism trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Shire sponsors the most Hypoparathyroidism trials on record, review their full trial history before evaluating a specific study. See Shire's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Hypoparathyroidism condition card totals 11 registered trials; most-linked intervention rhPTH (1-84); top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.